As you might know, Cytokinetics, Incorporated (NASDAQ:CYTK) just kicked off its latest quarterly results with some very strong numbers. The overall earnings picture was okay, with revenues of US$48m beating expectations by 12%. Statutory losses were US$1.37 per share, only marginally better than what the analysts had forecast. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we’ve aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Cytokinetics after the latest results.
Following the latest results, Cytokinetics’ 19 analysts are now forecasting revenues of US$443.0m in 2027. This would be a sizeable 291% improvement in revenue compared to the last 12 months. Losses are expected to be contained, narrowing 19% from last year to US$4.51. Before this latest report, the consensus had been expecting revenues of US$428.6m and US$4.60 per share in losses.
View our latest analysis for Cytokinetics
There were no major changes to the US$107consensus price target despite the higher revenue estimates, with the analysts seeming to believe that ongoing losses have a larger impact on the valuation. The consensus price target is just an average of individual analyst targets, so – it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on Cytokinetics, with the most bullish analyst valuing it at US$140 and the most bearish at US$78.00 per share. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Cytokinetics shareholders.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting Cytokinetics’ growth to accelerate, with the forecast 198% annualised growth to the end of 2027 ranking favourably alongside historical growth of 0.5% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 22% per year. Factoring in the forecast acceleration in revenue, it’s pretty clear that Cytokinetics is expected to grow much faster than its industry.
The Bottom Line
The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year’s earnings. We have forecasts for Cytokinetics going out to 2028, and you can see them free on our platform here.
Plus, you should also learn about the 2 warning signs we’ve spotted with Cytokinetics (including 1 which shouldn’t be ignored) .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
